Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24754048 | 0.85 | EPHX2 (0.48) | EPHX2CNR1PAOXCHRM1 | |
| SCHEMBL23269193 | 0.82 | CNR1 (0.50) | EPHX2CNR1HPGD | |
| SCHEMBL16924673 | 0.82 | EPHX2 (0.36) | EPHX2CNR1ALDH1A1PAOXHPGD | |
| SCHEMBL13697646 | 0.79 | LMNA (0.54) | EPHX2ALDH1A1LMNASLC15A2 | |
| SCHEMBL26713854 | 0.77 | CNR1 (0.35) | EPHX2CNR1ALDH1A1 | |
| SCHEMBL7664482 | 0.77 | ALDH1A1 (0.36) | EPHX2CNR1ALDH1A1LMNAHPGD | |
| SCHEMBL18976844 | 0.77 | ALDH1A1 (0.39) | EPHX2CNR1ALDH1A1LMNASLC15A2 | |
| SCHEMBL301539 | 0.75 | — | — | |
| SCHEMBL4721832 | 0.73 | — | — | |
| SCHEMBL8073220 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270309-A1 | MALEIMIDE GROUP-MODIFIED ANGIOGENESIS INHIBITOR HM-1 AND USE THEREOF | NANJING ANJI BIOLOGICAL TECHNOLOGY CO., LTD (CN) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270309-A1 | MALEIMIDE GROUP-MODIFIED ANGIOGENESIS INHIBITOR HM-1 AND USE THEREOF | VEGFA, VIP, VCAM1 | EPHX2 3420/4885CNR1 1414/4885ALDH1A1 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.